The most used methods for isoflavone
determination are liquid-liquid (LLE) and solid-phase extraction (SPE) .
For 12 weeks in a randomized trial, 70 women aged 18 to 40 years with polycystic ovary syndrome were assigned to consume 50 mg per day of a soy isoflavone
supplement or a placebo.
Because equol is believed to elicit greater biological reaction than other isoflavone
metabolites, it was anticipated that the clinical effectiveness of the ISP containing soy isoflavones
was dependent on eqoul.
Compared with the placebo group, soy isoflavone
administration significantly decreased circulating levels of insulin and other biological markers associated with insulin resistance - a condition whereby the body's tissues are resistant to the effects of insulin, which can lead to type 2 diabetes.
is one of the phytoestrogens with similar molecular structures to animal estrogen and has weak estrogenic effects.
The 66mg of isoflavone
that we use in this study is equivalent to eating an oriental diet, which is rich in soy foods."
Intergroup comparison revealed that decrease in the mean total AV lesion count before and after treatment was significant in isoflavone
160 mg group (pless than 0.05 ), while in the placebo, 40 mg, 80 mg, 120 mg groups it was insignificant (pgreater than 0.05 ).
The cultured cells were divided into six groups: control (vehicle), [MPP.sup.+] (250 [micro]mol/L) only, isoflavone
(10 [micro]M) + [MPP.sup.+] (250 [micro]mol/L) group, isoflavone
(10 [micro]M) only group, Z-YVAD-CHO (10 mM) + [MPP.sup.+] group, and Z-DEVD-CHO (10 mM) + [MPP.sup.+] group.
Methods: In this study, mice were divided into 4 groups (15 mice per group) of control, the dietary Soy Isoflavone
Extract (SIE, 100 mg/hg diet), the Docetaxel (DOCE, 10 mg/kg) injection and the combination of dietary soy isoflavone
extract and intravenous docetaxel injection (DOCE+SIE).
"It behooves us to examine the safety-related outcomes and rates of any adverse events in women consuming over-the-counter soy isoflavone
supplements, which could be 100 mg of isoflavones
a day or more," Dr.
Another alarm over soy and the breast: in 1998, researchers reported that genistein, a major soy isoflavone
, stimulated the growth of estrogen receptorpositive (ER+) breast tumors in a special strain of mice.
Concerns have been raised because of soy's isoflavone
content which could interfere with tamoxifen, a drug commonly used to treat breast cancer, and because of the potential for isoflavones
to stimulate cell growth.